



## NERVGEN PHARMA GRANTS STOCK OPTIONS

**Vancouver, Canada.** September 14, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 550,000 incentive stock options to Directors exercisable at a price of \$2.10 per share for a period of five years with vesting that is either time or performance based. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company’s stock option plan.

### **About NervGen**

NervGen is restoring life’s potential by creating innovative solutions for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The Company is initially developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer’s disease.

*For further information, please contact:*

*Huitt Tracey, Corporate Communications*

[htracey@nervgen.com](mailto:htracey@nervgen.com)

*604.362.6209*

*Nancy Thompson, Vorticom Public Relations*

[nancyt@vorticom.com](mailto:nancyt@vorticom.com)

*212.532.2208*

*Follow NervGen on Twitter (@NervgenP), LinkedIn (NervGen Pharma Corp.), and Facebook (facebook.com/nervgen/) for the latest news on the Company.*

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***